5-Amino-1MQ
5-Amino-1MQ is a selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme found at elevated levels in the white adipose tissue and liver of obese, diabetic mice. By blocking NNMT, it raises intracellular SAM and NAD+ levels in adipose tissue, a mechanism studied for its downstream effects on energy expenditure.
Part of KYIN Peptides' standard catalogue — see the product page for pricing. Note that 5-Amino-1MQ is a small molecule, not a peptide.
What Is 5-Amino-1MQ?
Unlike most compounds in KYIN's catalogue, 5-Amino-1MQ is not a peptide — it's a small-molecule quinolinium compound. Its story starts with a 2014 genetic study, not the compound itself: researchers led by William Kraus published “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity” in Nature, showing that the enzyme NNMT is elevated in the fat tissue and liver of obese, diabetic mice, and that knocking it down raised adipose SAM and NAD+ levels, increased energy expenditure, and protected mice against diet-induced obesity. That study established NNMT as a promising obesity target, but it used a genetic knockdown technique, not a drug. The compound itself came four years later, in 2018, when a team led by Stanley Watowich at the University of Texas Medical Branch introduced 5-Amino-1MQ as a small-molecule pharmacological tool to inhibit NNMT directly.
Research Focus
Research interest in 5-Amino-1MQ centers on NNMT's role at the intersection of NAD+ metabolism and adipose tissue biology, and what selectively blocking it can reveal about energy expenditure. It sits in KYIN's Weight Loss / Metabolic category alongside Retatrutide and MOTS-c, though its mechanism — enzyme inhibition rather than receptor agonism — is entirely distinct from either. See our Weight Loss / Metabolic research overview, or how it compares to MOTS-c and Retatrutide.
- Obesity and metabolic syndrome research
- Adipose-tissue NAD+/SAM biology
- Energy expenditure research
- SIRT1 signaling pathway studies
Clinical & Preclinical Trial Data
All available data is preclinical. The 2014 genetic knockdown study (Kraus et al., Nature) established NNMT as an obesity-relevant target in mice, and the 2018 pharmacology study (Neelakantan et al., Biochemical Pharmacology, University of Texas Medical Branch) introduced 5-Amino-1MQ itself, showing it reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake or lean mass. No human clinical trials of 5-Amino-1MQ have been conducted.
Availability
5-Amino-1MQ is part of KYIN Peptides' standard catalogue — see the product page for pricing, or contact us to order.
5-Amino-1MQ questions
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule quinolinium compound, not a peptide, that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in the fat tissue and liver of obese, diabetic mice. Blocking NNMT raises intracellular SAM and NAD+ levels in adipose tissue, a mechanism studied for its effects on energy expenditure.
Has 5-Amino-1MQ been tested in human trials?
No. All available data is preclinical. A 2014 genetic knockdown study (Kraus et al., Nature) established NNMT as an obesity-relevant target in mice, and a 2018 pharmacology study (Neelakantan et al., Biochemical Pharmacology, University of Texas Medical Branch) introduced 5-Amino-1MQ itself, showing it reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake or lean mass.
Does KYIN Peptides sell 5-Amino-1MQ?
Yes — 5-Amino-1MQ is part of our standard catalogue. See the product page for pricing.
Interested in 5-Amino-1MQ?
See pricing and order on the product page, or browse our other weight-loss and metabolic peptides.